OTC: IPSEF - Ipsen S.A.

Yield per half year: +2.5%
Dividend yield: +0.96%
Sector: Healthcare

Share chart Ipsen S.A.

Extended chart Simple chart
Financial Markets by TradingView

About Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma.

more details
The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета eur
Див.доход ао 0.9639
Дивиденд ао 1.16
Сайт https://www.ipsen.com
Цена ао 120.55
Change price per day: 0% (120.55)
Change price per week: 0% (120.55)
Change price per month: 0% (120.55)
Change price per 3 month: -3.84% (125.37)
Change price per half year: +2.5% (117.61)
Change price per year: +2.51% (117.6)
Change price per year to date: -3.84% (125.37)
All parameters

Underestimation

Title Value Grade
P/S 2.63 6
P/BV 2.15 7
P/E 12.77 8
EV/EBITDA 8.63 8
Total: 7.88

Efficiency

Title Value Grade
ROA, % 10.19 4
ROE, % 16.85 5
Total: 5

Dividends

Title Value Grade
Div yield, % 0.9639 2.4
DSI 0.8571 8.57
Total: 2.86

Debt

Title Value Grade
Debt/EBITDA 0.4137 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 22.79 4
Yield Ebitda, % 4.08 1
Yield EPS, % -1246.72 0
Total: 2.8
More



Head Job title Payment Year of birth
Mr. David Loew MD, CEO & Director 2.41M 1967 (58 years)
Mr. Aymeric Le Chatelier Executive VP & CFO 792.51k 1969 (56 years)
Dr. Aidan Murphy Ph.D. Executive VP and Head of Technical Operations N/A 1966 (59 years)
Mr. Craig Marks Vice-President of Investor Relations N/A
Mr. Francois Garnier Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer N/A 1962 (63 years)
Mr. Regis Mulot Executive VP & Chief Human Resources Officer N/A 1966 (59 years)
Ms. Dominique Bery Head of Nordics & Baltics N/A 1971 (54 years)
Mr. Bartosz Bednarz D.D.S. Executive VP and Head of Global Product & Portfolio Strategy N/A
Mr. Philippe Lopes-Fernandes CBO Executive VP & Chief Business Officer N/A
Dr. James Levine M.D., Ph.D. President of Fondation Ipsen

Address: France, Boulogne-Billancourt, 65 quai Georges Gorse - open in Google maps, open in Yandex maps
Website: https://www.ipsen.com